Related Experiment Videos
Small molecule CP-31398 induces reactive oxygen species-dependent apoptosis in human multiple myeloma
Yohei Arihara1, Kohichi Takada1,2, Yusuke Kamihara1
1Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Abstract:
Reactive oxygen species (ROS) are normal byproducts of a wide variety of cellular processes. ROS have dual functional roles in cancer cell pathophysiology. At low to moderate levels, ROS act as signaling transducers to activate cell proliferation, migration, invasion, and angiogenesis. In contrast, high levels of ROS induce cell death. In multiple myeloma (MM), ROS overproduction is the trigger for apoptosis induced by several anticancer compounds, including proteasome inhibitors. However, no drugs for which oxidative stress is the main mechanism of action are currently used for treatment of MM in clinical situations. In this study, we demonstrate that the p53-activating small molecule CP-31398 (CP) effectively inhibits the growth of MM cell lines and primary MM isolates from patients. CP also suppresses the growth of MM xenografts in mice. Mechanistically, CP was found to induce intrinsic apoptosis in MM cells via increasing ROS production. Interestingly, CP-induced apoptosis occurs regardless of the p53 status, suggesting that CP has additional mechanisms of action. Our findings thus indicate that CP could be an attractive candidate for treatment of MM patients harboring p53 abnormalities; this satisfies an unmet clinical need, as such individuals currently have a poor prognosis.
Insights
The small molecule CP-31398 (CP) effectively inhibits multiple myeloma (MM) growth by increasing reactive oxygen species (ROS) and inducing apoptosis. This compound shows promise for treating MM, especially in patients with p53 abnormalities.
Area of Science:
- Oncology
- Cellular Biology
- Pharmacology
Background:
- Reactive oxygen species (ROS) play a dual role in cancer, acting as signaling molecules at low levels and inducing cell death at high levels.
- In multiple myeloma (MM), elevated ROS trigger apoptosis with certain anticancer drugs, but no treatments currently target oxidative stress as a primary mechanism.
- Patients with p53 abnormalities in MM have a poor prognosis, highlighting an unmet clinical need.
Purpose of the Study:
- To investigate the efficacy of the p53-activating small molecule CP-31398 (CP) in inhibiting multiple myeloma (MM) growth.
- To elucidate the mechanism of action of CP in MM, focusing on its role in reactive oxygen species (ROS) production and apoptosis.
- To assess the potential of CP as a therapeutic agent for MM, particularly in patients with p53 abnormalities.
Main Methods:
- In vitro studies using MM cell lines and primary MM isolates from patients.
- In vivo studies involving MM xenografts in mice.
- Assessment of CP-induced changes in ROS levels and apoptosis in MM cells.
Main Results:
- CP effectively inhibited the growth of MM cell lines and primary MM isolates.
- CP suppressed the growth of MM xenografts in mice.
- CP induced intrinsic apoptosis in MM cells by increasing ROS production, irrespective of p53 status.
Conclusions:
- CP demonstrates significant anti-MM activity both in vitro and in vivo.
- CP-induced apoptosis in MM cells is mediated by increased ROS production.
- CP represents a promising therapeutic candidate for MM, especially for patients with p53 abnormalities, addressing a critical unmet need.